Investment analysts at Rodman & Renshaw initiated coverage on shares of TuHURA Biosciences (NASDAQ:HURA – Get Free Report) in a report released on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Rodman & Renshaw’s price objective indicates a potential upside of 145.54% from the stock’s previous close.
Separately, Maxim Group began coverage on TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price target on the stock.
Check Out Our Latest Stock Report on TuHURA Biosciences
TuHURA Biosciences Price Performance
About TuHURA Biosciences
TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Recommended Stories
- Five stocks we like better than TuHURA Biosciences
- What is the S&P/TSX Index?
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- Where to Find Earnings Call Transcripts
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- What to Know About Investing in Penny Stocks
- 2 Underrated Quantum Computing Companies Starting to Rally
Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
